Overview

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Status:
RECRUITING
Trial end date:
2030-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if ivonescimab can help to control previously treated, metastatic colorectal cancer.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Akesobio Australia Pty Ltd
Summit Therapeutics